Streetbeat News

Products Services

NXGL

Nexgel (NXGL) has entered into a partnership with Stada Arzneimittel to distribute and commercialize over-the-counter (OTC) consumer health products in North America starting in 2024.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 1:07 pm

THAR

Tharimmune reported positive Phase 1 results for TH104, its treatment for pruritus in chronic liver disease patients, showing a 33.3% reduction in itching intensity. The drug was well tolerated, with no unexpected adverse events. The company is funded into early 2025 and anticipates US PK data and Phase 2a results in 2024.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 1:05 pm

AAPL

CI

KO

M

TSLA

Bitcoin's social dominance has fallen by over 30% as its price dropped below $42,000. An investor group has proposed a $5.8 billion acquisition of Macy's. Cigna has called off its merger with Humana and is moving towards a $10 billion buyback strategy. Apple's analyst has raised the price target to $250, anticipating a $4 trillion valuation by 2024. Tesla's Cybertruck is nearing delivery, and the vehicle has been approved for a $7,500 federal tax credit. Coca-Cola is testing alcoholic beverages in India, and Starlink kits are now available at Costco.

Portfolio Pulse from Akanksha Bakshi

December 11, 2023 | 1:04 pm

KTTA

Pasithea Therapeutics reported that its drug PAS-004 has shown anti-tumor efficacy in preclinical in vivo studies involving NRAS mutation cancer xenograft models. The drug was effective with a once-daily dose in these models.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 1:03 pm

ERAS

Erasca, Inc. has been granted FDA Fast Track Designation for its pan-RAF inhibitor, Naporafenib, for treating patients with advanced NRAS-mutated melanoma. This designation could expedite the development and review process for Naporafenib, potentially bringing it to market more quickly if it proves to be safe and effective.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 1:02 pm

BKYI

BIO-key International, Inc. has partnered with Ping Identity to include its biometric authentication technology in the Ping Identity Integration Directory. This collaboration allows Ping customers to use BIO-key's technology with the PingOne Cloud Platform, enhancing security and user experience. The integration is part of Ping Identity's Global Technology Partner Program, aiming to improve digital customer experiences without compromising security. BIO-key's Identity-Bound Biometrics offer passwordless authentication, contributing to a more secure and frictionless digital environment.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 1:00 pm

NVDA

Nvidia Corp (NASDAQ:NVDA) is expanding its global presence, focusing on partnerships in Vietnam with leading tech firms to develop AI and digital infrastructure. The company has invested $250 million in Vietnam and is considering establishing an R&D facility there. Nvidia's stock has seen a 232% year-to-date increase. Meanwhile, YTL Power International's shares surged after announcing a $4.3 billion AI data center partnership with Nvidia in Malaysia. Analyst Matt Ramsay of TD Cowen maintains a Buy rating on Nvidia, which traded slightly higher premarket on Monday.

Portfolio Pulse from Anusuya Lahiri

December 11, 2023 | 1:00 pm

AMAT

ASML

GFS

IBM

MU

ON

WOLF

New York State is investing $10 billion to create a semiconductor research facility at the University at Albany, in collaboration with NY Creates and major chip companies. The facility will feature advanced equipment from ASML Holding NV and involve key industry players like IBM, Micron Technology, Applied Materials, and Tokyo Electron. The project aims to make New York a significant research hub, create 700 jobs, attract $9 billion in private investment, and reduce reliance on foreign chip technologies. GlobalFoundries, ON Semiconductor, and Wolfspeed also have existing facilities in New York, with Micron planning a new factory near Syracuse.

Portfolio Pulse from Anusuya Lahiri

December 11, 2023 | 12:57 pm

NVS

Novartis AG (NYSE:NVS) reported positive Phase 3 study results for iptacopan in treating C3 glomerulopathy (C3G), a rare kidney disease. The study met its primary endpoint, showing significant proteinuria reduction. Iptacopan, branded as Fabhalta, was recently FDA-approved for a rare blood disorder. Regulatory submissions for C3G treatment are expected in 2024. NVS shares rose 0.53% in premarket trading.

Portfolio Pulse from Vandana Singh

December 11, 2023 | 12:56 pm

ATNM

Actinium Pharmaceuticals presented positive data on Iomab-B and Actimab-A for treating relapsed or refractory Acute Myeloid Leukemia at the ASH conference. Four presentations highlighted the outcomes, suggesting potential for these treatments in a challenging patient population.

Portfolio Pulse from Benzinga Newsdesk

December 11, 2023 | 12:55 pm